CT Imaging for Guiding PA-TACE for HCC

Postoperative adjuvant transarterial chemoembolization (PA-TACE) may improve survival outcomes in a subset of patients with resected hepatocellular carcinoma (HCC), reliable biomarkers for the criterion for the selection of candidates are lacking. The present study aimed to evaluate whether CT imaging can provide more value for predicting benefit from PA-TACE.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Carcinoma, Hepatocellular Adenocarcinoma Carcinoma Digestive System Diseases Digestive System Neoplasms Liver Diseases Liver Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

ZhuJiang Hospital of Southern Medical University

Guangzhou, Guangdong, 510280, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

CT scans acquired no more than one month before surgery
Confirmation of HCC diagnosis by pathological examination
Curative surgical resection

Exclusion criteria

Prior antitumor treatment
Macrovascular thrombosis or metastasis
Perioperative mortality
Unqualified image artifacts
Tumor rupture
MVI status not reported

Treatment and study plan

postoperative adjuvant transarterial chemoembolization

Procedure

HCC patients received hepatectomy and PA-TACE.

Primary outcomes

Overall survival

Time frame: the date of hepatectomy to the last follow-up or until death, whichever came first, assessed up to 120 months.

Overall survival was calculated from the date of hepatectomy to the last follow-up or until death, whichever came first.

Sponsors and collaborators

Lead sponsor

Zhujiang Hospital

Other

Registry information

Official study title

CT Imaging for Guiding Postoperative Adjuvant Transarterial Chemoembolization for Hepatocellular Carcinoma

Important dates

Study start: 2019
Primary completion: 2025
Study completion: 2025
First posted: Dec 5, 2023
Registry last updated: Jul 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed